Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone

Zalewska-Kaszubska, Jadwiga; Górska, Dorota; Dyr, Wanda; Czarnecka, E

doi:10.1016/j.pbb.2006.07.028

Cited by 23 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further, elevated frontal/temporal cortical μ-opioid receptor binding has been observed in cocaine dependence, the degree of which was shown to positively correlate with self-reported cocaine craving (Gorelick et al, 2005), and relate to relapse following treatment (Ghitza et al, 2010;Gorelick et al, 2008). NTX has been shown to block ethanol-induced β-endorphin and subsequent dopamine release in the nucleus accumbens and provide a blockade of ethanol-induced β-endorphin inhibition of GABAergic inhibitory interneurons in the ventral tegmental area (Johnson, 2008;Zalewska-Kaszubska et al, 2006). The decrease in amphetamine-induced dopamine Figure 3 Subjective response scores (drug effects questionnaire (DEQ)), presented with standard errors, at baseline (BA) and change from baseline at 5,10,15,20,30,60,90, and 120 min following methamphetamine (MA) administration, during both placebo and naltrexone (NTX) conditions.…”

Section: Discussionmentioning

confidence: 99%

The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study

Ray

Bujarski

Courtney

et al. 2015

Neuropsychopharmacol

View full text Add to dashboard Cite

Methamphetamine (MA) use disorder is a serious psychiatric condition for which there are no FDA-approved medications. Naltrexone (NTX) is an opioid receptor antagonist with demonstrated efficacy, albeit moderate, for the treatment of alcoholism and opioid dependence. Preclinical and clinical studies suggest that NTX may be useful for the treatment of MA use disorder. To inform treatment development, we conducted a double-blind, randomized, crossover, placebo-controlled human laboratory study of NTX. Non-treatmentseeking individuals meeting DSM-IV criteria for MA abuse or dependence (n = 30) completed two separate 5-day inpatient stays. During each admission, participants completed testing sessions comprised of MA cue-reactivity and intravenous MA administration (30 mg) after receiving oral NTX (50 mg) or placebo for 4 days. This study tested the hypotheses that NTX would (a) attenuate cue-induced MA craving, and (b) reduce subjective responses to MA administration. Results largely supported the study hypotheses such that (a) NTX significantly blunted cue-induced craving for MA and (b) attenuated several of the hedonic subjective effects of MA, including craving, during controlled MA administration and as compared with placebo. NTX decreased overall subjective ratings of 'crave drug,' 'stimulated,' and 'would like drug access,' decreased the the post-MA administration timecourse of 'anxious' and increased ratings of 'bad drug effects,' as compared with placebo. These findings support a potential mechanism of action by showing that NTX reduced cue-induced craving and subjective responses to MA. This is consistent with positive treatment studies of NTX for amphetamine dependence, as well as ongoing clinical trials for MA.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study

Ray

Bujarski

Courtney

et al. 2015

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Further, alcohol intake increases beta-endorphin release in brain regions such as the nucleus accumbens [22][23][24], an effect that is blocked by naltrexone [25]. Mu receptor antagonists such as naltrexone and naloxone also suppress ethanol intake across a wide range of animal paradigms [26][27][28][29][30][31][32][33][34][35][36] cf.…”

Section: Opioids: Mu Receptor Antagonist -Naltrexone Basic Science Anmentioning

confidence: 99%

Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings

Johnson

2008

Biochemical Pharmacology

244

185

View full text Add to dashboard Cite

The past decade has seen an expansion of research and knowledge on pharmacotherapy for the treatment of alcohol dependence. The Food and Drug Administration (FDA)-approved medications naltrexone and acamprosate have shown mixed results in clinical trials. Oral naltrexone and naltrexone depot formulations have generally demonstrated efficacy at treating alcohol dependence, but their treatment effect size is small, and more research is needed to compare the effects of different doses on drinking outcome. Acamprosate has demonstrated efficacy for treating alcohol dependence in European trials, but with a small effect size. In U.S. trials, acamprosate has not proved to be efficacious. Research continues to explore which types of alcohol-dependent individual would benefit the most from treatment with naltrexone or acamprosate. The combination of the two medications demonstrated efficacy for treating alcohol dependence in one European study but not in a multi-site U.S. study. Another FDA-approved medication, disulfiram, is an aversive agent that does not diminish craving for alcohol. Disulfiram is most effective when given to those who are highly compliant or who are receiving their medication under supervision. Of the non-approved medications, topiramate is among the most promising, with a medium effect size in clinical trials. Another promising medication, baclofen, has shown efficacy in small trials. Serotonergic agents such as selective serotonin reuptake inhibitors and the serotonin-3 receptor antagonist, ondansetron, appear to be efficacious only among certain genetic subtypes of alcoholic. As neuroscientific research progresses, other promising medications, as well as medication combinations, for treating alcohol dependence continue to be explored.

show abstract

“…Treatment of Warsaw High and Low Alcohol Preferring rats with the opioid antagonist naltrexone, stopped the plasma β-endorphin increase after EtOH administration in low-preference rats, and normalized β-endorphin plasma levels in high-preferring rats so that before and after alcohol exposure plasma levels were similar. These results indicate the clinical effectiveness of naltrexone in treatment of alcoholism may in part be due to both normalization of plasma β-endorphin levels and an attenuation of alcohol-rewarding properties (Zalewska-Kaszubska et al, 2006). In the same strains of rats, β-endorphin levels and EtOH intake were examined following treatment with acamprosate, which is approved for relapse prevention in withdrawing alcoholics.…”

Section: β-Endorphin and Acute Alcohol Exposurementioning

confidence: 90%

“…Opioids are primarily known for their analgesic properties, but they are highly implicated in the physiological rewarding effects of alcohol and other drugs of abuse (Wei & Loh, 1976;Van Ree, 1979;Zalewska-Kaszubska et al, 2006;see Crabbe et al, 2006 for review) as well as a wide array of other behavioral states. One class of endogenous opioids is the endorphins.…”

Section: The Hypothalamo-pituitary-adrenocortical Axis and -Endorphinmentioning

confidence: 99%

β-Endorphin and Alcoholism

Barry¹,

Grisel²

2012

Neuroscience - Dealing With Frontiers

View full text Add to dashboard Cite

Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone

Cited by 23 publications

References 32 publications

The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study

The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study

Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings

β-Endorphin and Alcoholism

Contact Info

Product

Resources

About

Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone

Cited by 23 publications

References 32 publications

The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study

The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study

Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings

&beta;-Endorphin and Alcoholism

Contact Info

Product

Resources

About

β-Endorphin and Alcoholism